Clinical Updates
Latest news
1078 articles · 20 / page
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.
Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer
The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.
Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma
The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.
Comparing the PREVENT and PCE Models for 10-Year ASCVD Risk Prediction: Insights from a Large Real-World Cohort
This review evaluates PREVENT versus PCE models for estimating 10-year ASCVD risk focusing on accuracy in patients with and without statin therapy, highlighting implications for personalized prevention.
Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo
Ferritin-Guided Iron Supplementation in Blood Donors: Evidence Synthesis and Clinical Implications from the FORTE Trial and Related Studies
Iron supplementation guided by ferritin levels effectively mitigates iron deficiency and anaemia in regular blood donors, offering a practical alternative or adjunct to extending donation intervals.
Innovative DEP-SN38 Nanoparticle Delivery Shows Promise in Advanced Solid Tumors: Safety and Preliminary Efficacy Unveiled
This phase I study demonstrates that DEP-SN38, a dendrimer-nanoparticle conjugate of SN38, is well tolerated with minimal gastrointestinal toxicity and shows encouraging antitumor activity in heavily pretreated advanced solid tumors.
Methylcobalamin Significantly Reduces Severe Hand-Foot Syndrome in HER2 Negative Early Breast Cancer Patients Receiving Capecitabine: Results from a Phase 3 Randomised Trial
Oral methylcobalamin notably decreased the incidence of grade ≥2 hand-foot syndrome in patients with HER2 negative early breast cancer undergoing adjuvant capecitabine treatment, without added safety concerns, improving treatment adherence
Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials
A pooled analysis of NIFTY and NALIRICC trials demonstrates that liposomal irinotecan combined with 5-FU/leucovorin significantly improves progression-free survival and response rates in previously treated biliary tract cancer, with notable
Total Tumor Volume: A Superior Predictor of Survival and Chemotherapy Response in Colorectal Cancer Liver Metastases
This study reveals that total tumor volume (TTV) more accurately predicts overall survival and response to induction chemotherapy than RECIST1.1 in colorectal cancer liver metastases, offering a promising tool for personalized treatment dec
Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial
The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.
Browse by specialty
Open language-specific specialty feeds and department pages.